Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc (CSE:DRUG)

72.53 +1.94 (+2.75%)
Delayed Quote Updated: 1:07 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bright Minds Biosciences Inc

News headline image
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational effects as a near-death experience (NDE). The... 
Via PressReach
Topics Supply Chain
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking... 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.